A Phase 2 interventional study of TAF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 30 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-27.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 13th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 2, and was the 4th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18–70
First People's Hospital of Hangzhou · Sites in China
Ages 20–40 · Women only
Jidong Jia · Sites in China
Ages 18–69
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 20+
The Task Force for Global Health · Sites in Thailand
Healthy volunteers
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 14
First in 2012; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 124 across the 26 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 13th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2017, is one of 15 in phase 2, and was the 29th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing tenofovir alafenamide in Hepatitis B, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, from their registry updates:
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic impairment.
Key Inclusion Criteria:
All Participants (Parts A and B):
Part A Only (renal impairment):
Maintained on TDF and/or other OAV treatment(s) for CHB for at least 48 weeks and with viral suppression (HBV deoxyribonucleic acid [DNA] \< lower limit of quantitation [LLOQ]) for ≥ 6 months prior to screening
Part B Only (hepatic impairment):
Maintained on TDF and/or other OAV(s) for CHB for at least 48 weeks and with viral suppression (HBV DNA \< LLOQ) for ≥ 6 months prior to screening
Key Exclusion Criteria:
All Individuals (Parts A \& B):
Part A Only (Renal Impairment):
Abnormal hematological and biochemical parameters, including:
Part B Only (Hepatic Impairment):
Abnormal hematological and biochemical parameters, including
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
Drug: TAF
Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
Drug: TAF
Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
Drug: TAF
Tablet administered orally once daily
Also known as: Vemlidy®
Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24
The percentage of participants with HBV DNA \< 20 IU/mL at Week 24 was determined by the Missing = Failure (M = F) approach.
Time frame: Week 24
Percentage of Participants Who Experienced Graded Treatment-Emergent Adverse Events (AEs) at Week 24
Treatment-emergent AEs were defined as: * Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; * Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; * Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
Time frame: Week 24
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 24
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Week 24
Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 48
Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
Time frame: Week 48
Percentage of Participants Who Experienced Graded Treatment-Emergent AEs at Week 96
Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
Time frame: Week 96
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 48
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Week 48
Percentage of Participants Who Experienced Graded Treatment-Emergent Laboratory Abnormalities at Week 96
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Week 96
Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 24 minus the value at Baseline.
Time frame: Baseline, Week 24
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
Time frame: Baseline, Week 48
Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
Time frame: Baseline, Week 96
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 24
Percent Change From Baseline in Hip BMD at Week 48
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 48
Percent Change From Baseline in Hip BMD at Week 96
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 96
Percent Change From Baseline in Spine BMD at Week 24
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 24
Percent Change From Baseline in Spine BMD at Week 48
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 48
Percent Change From Baseline in Spine BMD at Week 96
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
Time frame: Baseline, Week 96
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48
The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.
Time frame: Weeks 48
Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96
The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.
Time frame: Weeks 96
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.
Time frame: Week 24
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.
Time frame: Week 48
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.
Time frame: Week 96
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.
Time frame: Week 24
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.
Time frame: Weeks 48
Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.
Time frame: Weeks 96
Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Serological Response: Loss of HBsAg at Week 48
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Serological Response: Loss of HBsAg at Week 96
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 96
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 96
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
Time frame: Week 96
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
Time frame: Week 96
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 24 by Central Laboratory and the American Association for the Study of Liver Diseases (AASLD) Criteria
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Normal ALT at Week 48 by Central Laboratory and the AASLD Criteria
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Normal ALT at Week 96 by Central Laboratory and the AASLD Criteria
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 96
Percentage of Participants With Normalized ALT at Week 24 by Central Laboratory and the AASLD Criteria
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 24
Percentage of Participants With Normalized ALT at Week 48 by Central Laboratory and the AASLD Criteria
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 48
Percentage of Participants With Normalized ALT at Week 96 by Central Laboratory and the AASLD Criteria
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
Time frame: Week 96
Change From Baseline in FibroTest® Score at Week 24
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 24 minus the value at Baseline.
Time frame: Baseline, Week 24
Change From Baseline in FibroTest® Score at Week 48
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
Time frame: Baseline, Week 48
Change From Baseline in FibroTest® Score at Week 96
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
Time frame: Week 96
Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline, Week 24
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 48
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline, Week 48
Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 96
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline, Week 96
Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline, Week 24
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 48
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline, Week 48
Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline, Week 96
Participants were enrolled at study sites in Asia Pacific, North America, New Zealand and Europe. The first participant was screened on 29 June 2017. The last study visit occurred on 04 September 2020.
| Milestone | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Started | 78 | 15 | 31 |
| Completed | 67 | 14 | 25 |
| Not completed | 11 | 1 | 6 |
| Withdrew: Withdrew consent | 5 | 0 | 2 |
| Withdrew: Death | 2 | 1 | 2 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Investigator's discretion | 2 | 0 | 1 |
The percentage of participants with HBV DNA \< 20 IU/mL at Week 24 was determined by the Missing = Failure (M = F) approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24 | 97.4 | 100.0 | 100.0 |
Treatment-emergent AEs were defined as: * Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; * Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; * Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Treatment-emergent AEs | 53.8 | 73.3 | 54.8 |
| Grade 3 and Above Treatment-emergent AEs | 6.4 | 13.3 | 6.5 |
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Graded Laboratory Abnormality | 96.2 | 100.0 | 90.3 |
| Grade 3 and Above Laboratory Abnormality | 11.5 | 46.7 | 48.4 |
Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Treatment-emergent AE | 71.8 | 86.7 | 71.0 |
| Grade 3 and Above Treatment-emergent AEs | 15.4 | 20.0 | 12.9 |
Treatment-emergent AEs were defined as: Any AEs with an onset date on or after the study drug start date and no later than the study drug stop date + 3 days after permanent discontinuation of study drug; Any AEs with onset date on or after the study drug start date for those who have not permanently discontinued study drug; Any AEs leading to premature discontinuation of study drug. The most severe graded AE from all tests was counted for each participant.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Treatment-emergent AEs | 74.4 | 100.0 | 77.4 |
| Grade 3 and Above treatment-emergent AEs | 17.9 | 26.7 | 25.8 |
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Graded Laboratory Abnormality | 96.2 | 100.0 | 90.3 |
| Grade 3 | 12.8 | 40.0 | 41.9 |
| Grade 4 | 0 | 26.7 | 9.7 |
Graded treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the date of last dose of study drug + 3 days for participants who permanently discontinued study drug or the last available date in the database snapshot for participants who were on treatment at the time of the analysis. The most severe graded abnormality from all tests was counted for each participant.
| percentage of particpants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Any Graded Laboratory Abnormality | 96.2 | 100.0 | 100.0 |
| Grade 3 | 15.4 | 46.7 | 41.9 |
| Grade 4 | 1.3 | 26.7 | 12.9 |
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 24 minus the value at Baseline.
| mL/min | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part B: Hepatic Impairment |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFRcg) in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 24 | -0.4 (-3.9 to 4.5) | 1.9 (-5.6 to 12.2) |
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
| mL/min | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part B: Hepatic Impairment |
|---|---|---|
| Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 48 | -0.5 (-4.1 to 3.0) | 1.2 (-13.5 to 6.5) |
GFR is a measure of the rate at which blood is filtered by the kidney. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. eGFRcg = (140 - age in years) x (body weight in kg) x (0.85 if female) divided by 72 x serum creatinine in mg/dL. Moderate renal impairment= 30 mL/min ≤ eGFRCG ≤ 59 mL/min Severe renal impairment= 15 mL/min ≤ eGFRCG \< 30 mL/min Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
| mL/min | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part B: Hepatic Impairment |
|---|---|---|
| Change From Baseline in eGFRcg in Participants With Moderate or Severe Renal Impairment and Hepatically Impaired Participants at Week 96 | 1.0 (-2.8 to 4.5) | -2.4 (-11.4 to 10.7) |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 24 | 0.135 ± 1.8348 | 0.322 ± 2.1835 | 0.322 ± 2.5105 |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 48 | 0.565 ± 2.6160 | -1.075 ± 3.6355 | -0.221 ± 3.0158 |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 96 | 0.425 ± 2.8381 | -0.834 ± 4.7171 | 0.277 ± 3.2549 |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 24 | 1.229 ± 3.4252 | 0.683 ± 3.1370 | 1.258 ± 2.3416 |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 | 1.516 ± 3.7486 | 0.016 ± 4.1636 | 0.535 ± 3.4386 |
Percent change = Change from baseline at a postbaseline visit/baseline \* 100%.
| percent change | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 96 | 1.293 ± 4.4136 | -0.283 ± 4.5327 | -0.249 ± 3.9127 |
The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 48 | 92.3 | 93.3 | 100.0 |
The percentage of participants with HBV DNA \< 20 IU/mL at Week 48 was determined by the Missing = Failure (M = F) approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants Achieving Virologic Response (Plasma HBV DNA < 20 IU/mL) at Week 96 | 83.3 | 86.7 | 77.4 |
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ Lower Limit of Detection [LLOD]) at Week 24 | 21.8 | 40.0 | 22.6 |
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 48 | 26.9 | 26.7 | 25.8 |
The percentage of participants with HBV DNA \< 20 IU/mL and target detected (≥ LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Detected (≥ LLOD) at Week 96 | 14.1 | 20.0 | 0 |
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 24 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 24 | 75.6 | 60.0 | 77.4 |
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 48 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 48 | 65.4 | 66.7 | 74.2 |
The percentage of participants with HBV DNA \< 20 IU/mL and target not detected (\< LLOD; i.e. 10 IU/mL) at Week 96 was determined by the M = F approach.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 20 IU/mL and Target Not Detected (< LLOD) at Week 96 | 69.2 | 66.7 | 77.4 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of Hepatitis B s-Antigen (HBsAg) at Week 24 | 0 | 0 | 0 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of HBsAg at Week 48 | 0.0 | 6.7 | 3.3 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of HBsAg at Week 96 | 0 | 0 | 6.7 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 24 | 0 | 0 | 0 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 48 | 0 | 0 | 0 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBs at Week 96 | 0 | 0 | 0 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 24 | 0 | 0 | 0 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 48 | 0 | 0 | 0 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Loss of HBeAg in HBeAg-Positive Participants at Week 96 | 0 | 33.3 | 0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 24 | 0 | 0 | 0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 48 | 0 | 0 | 0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb test changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Percentage of Participants With Serological Response: Seroconversion to Anti-HBe in HBeAg-Positive Participants at Week 96 | 0 | 33.3 | 0 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| ALT by central laboratory | 92.3 | 93.3 | 83.9 |
| ALT by AASLD criteria | 87.2 | 93.3 | 80.6 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| ALT by central laboratory | 89.7 | 86.7 | 90.3 |
| ALT by AASLD criteria | 87.2 | 80.0 | 80.6 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| ALT by central laboratory | 82.1 | 86.7 | 71.0 |
| ALT by AASLD criteria | 74.4 | 86.7 | 58.1 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Normalized ALT by Central Laboratory | 66.7 | — | 50.0 |
| Normalized ALT by AASLD Criteria | 40.0 | — | 60.0 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Normalized ALT by Central Laboratory | 33.3 | — | 75.0 |
| Normalized ALT by AASLD Criteria | 60.0 | — | 60.0 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to \< 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to \< 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. The M = F approach was used for this analysis.
| percentage of participants | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Normalized ALT by Central Laboratory | 33.3 | — | 50.0 |
| Normalized ALT by AASLD Criteria | 20.0 | — | 50.0 |
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 24 minus the value at Baseline.
| units on a scale | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Change From Baseline in FibroTest® Score at Week 24 | -0.01 ± 0.099 | -0.01 ± 0.064 | -0.05 ± 0.106 |
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline.
| units on a scale | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Change From Baseline in FibroTest® Score at Week 48 | -0.03 ± 0.102 | -0.01 ± 0.071 | -0.03 ± 0.102 |
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline.
| units on a scale | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment |
|---|---|---|---|
| Change From Baseline in FibroTest® Score at Week 96 | -0.01 ± 0.114 | 0.03 ± 0.107 | -0.02 ± 0.118 |
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in Child-Pugh-Turcotte (CPT) Score in Hepatically Impaired Participants at Week 24 | 0 ± 1.1 |
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 48 | 0 ± 1.1 |
CPT scores grade the severity of cirrhosis and are used to determine the need for liver transplantation. Scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in CPT Score in Hepatically Impaired Participants at Week 96 | 0 ± 1.2 |
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in Model for End-Stage Liver Disease (MELD) Score in Hepatically Impaired Participants at Week 24 | -0.6 ± 1.94 |
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 48 | 0.1 ± 2.35 |
MELD scores are used to assess prognosis and suitability for liver transplantation. Scores can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Part B: Hepatic Impairment |
|---|---|
| Change From Baseline in MELD Score in Hepatically Impaired Participants at Week 96 | -1.0 ± 1.61 |
Collected over Adverse Events: From the first dose date up to last dose date (maximum: 108.1 weeks) plus 3 days; All-Cause Mortality: Enrollment up to last dose date (maximum: 166.2 weeks) plus 3 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A (Renal Impairment): Moderate or Severe Renal Impairment | 2/78 (2.6%) | 12/78 (15.4%) | 34/78 (43.6%) |
| Part A (Renal Impairment): End Stage Renal Disease (Cohort 2) | 1/15 (6.7%) | 8/15 (53.3%) | 15/15 (100%) |
| Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair | 2/31 (6.5%) | 10/31 (32.3%) | 23/31 (74.2%) |
| Event | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease (Cohort 2) | Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair |
|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/78 | 2/15 | 0/31 |
| AnaemiaBlood and lymphatic system disorders | 0/78 | 1/15 | 0/31 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/78 | 1/15 | 0/31 |
| Deafness neurosensoryEar and labyrinth disorders | 0/78 | 1/15 | 0/31 |
| Abdominal painGastrointestinal disorders | 0/78 | 1/15 | 0/31 |
| ColitisGastrointestinal disorders | 0/78 | 1/15 | 0/31 |
| Intestinal obstructionGastrointestinal disorders | 0/78 | 1/15 | 0/31 |
| Catheter site dischargeGeneral disorders | 0/78 | 1/15 | 0/31 |
| BacteraemiaInfections and infestations | 0/78 | 1/15 | 0/31 |
| Lower respiratory tract infectionInfections and infestations | 0/78 | 1/15 | 0/31 |
| Event | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease (Cohort 2) | Part B (Hepatic Impairment): Moderate or Severe Hepatic Impair |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/78 | 4/15 | 3/31 |
| HypertensionVascular disorders | 2/78 | 4/15 | 1/31 |
| AnaemiaBlood and lymphatic system disorders | 2/78 | 3/15 | 1/31 |
| DiarrhoeaGastrointestinal disorders | 3/78 | 3/15 | 6/31 |
| PyrexiaGeneral disorders | 0/78 | 3/15 | 5/31 |
| Upper respiratory tract infectionInfections and infestations | 11/78 | 3/15 | 6/31 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/78 | 3/15 | 1/31 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/78 | 3/15 | 2/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/78 | 0/15 | 6/31 |
| Bone density decreasedInvestigations | 1/78 | 0/15 | 5/31 |
The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 66 ± 10.1 | 54 ± 12.8 | 55 ± 10.8 | 61 ± 11.8 |
| Sex: Female, Male(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| Female | 21 | 3 | 10 | 34 |
| Male | 57 | 12 | 21 | 90 |
| Race/Ethnicity, Customized(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 1 | 1 |
| Ethnicity — Not Hispanic or Latino | 78 | 15 | 30 | 123 |
| Race/Ethnicity, Customized(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| Race — Asian | 59 | 13 | 25 | 97 |
| Race — Black or African American | 3 | 0 | 1 | 4 |
| Race — Native Hawaiian or Pacific Islander | 0 | 2 | 0 | 2 |
| Race — White | 15 | 0 | 4 | 19 |
| Race — Other | 1 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| New Zealand | 0 | 2 | 0 | 2 |
| Canada | 22 | 0 | 3 | 25 |
| South Korea | 12 | 3 | 5 | 20 |
| Hong Kong | 14 | 1 | 2 | 17 |
| United States | 3 | 0 | 7 | 10 |
| Taiwan | 13 | 9 | 11 | 33 |
| Italy | 13 | 0 | 2 | 15 |
| United Kingdom | 1 | 0 | 1 | 2 |
| Alanine Aminotransferase (ALT)(Units/Liter (U/L)) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| Mean | 20 ± 9.6 | 14 ± 5.2 | 28 ± 12.4 | 21 ± 10.8 |
| ALT Level Based on Central Lab Normal Range(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| ≤ ULN | 75 | 15 | 27 | 117 |
| > ULN - 5xULN | 3 | 0 | 4 | 7 |
| > 5xULN | 0 | 0 | 0 | 0 |
| ALT Level Based on 2018 American Association for the Study of Liver Diseases (AASLD) Normal Range(Participants) | Part A (Renal Impairment): Moderate or Severe Renal Impairment | Part A (Renal Impairment): End Stage Renal Disease | Part B: Hepatic Impairment | Total |
|---|---|---|---|---|
| ≤ ULN | 73 | 15 | 21 | 109 |
| > ULN - 5xULN | 5 | 0 | 10 | 15 |
| > 5xULN | 0 | 0 | 0 | 0 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jun 2017 to primary completion in Mar 2019, 20 months.
Results were first posted in Apr 2020, 1 year after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 20 months is close to that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide